Drug profile · INN
dapagliflozin
FORXIGA
dapagliflozin (FORXIGA) is a sodium/glucose cotransporter 2 inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Drug details — dapagliflozin
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 1
- Programs
- 52
- Data quality
- 0.89
Quick answer
dapagliflozin (FORXIGA) is a sodium/glucose cotransporter 2 inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium/glucose cotransporter 2 inhibitor
Primary target: Sodium/glucose cotransporter 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is dapagliflozin?
dapagliflozin (FORXIGA) is a sodium/glucose cotransporter 2 inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dapagliflozin?
FORXIGA is a marketed brand name for dapagliflozin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dapagliflozin?
dapagliflozin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.